ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

APRE vs ENVB // PIOTROSKI F-SCORE QUALITY

Aprea Therapeutics Inc. (NASDAQ) VS. Enveric Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: APRE 0 — ENVB 3
▲ PIOTROSKI F-SCORE QUALITY LEADER: ENVB
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APRE VS. ENVB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC APRE ENVB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 2/9 3/9 -1.00 ENVB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.1 51.3 -14.20 ENVB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $6.2M $6.5M -$319.8K ENVB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR APRE REV ENVB REV APRE GROSS % ENVB GROSS % APRE FCF ENVB FCF
FY 2025 $0 $0 — — -$12.9M -$8.1M
FY 2024 $0 $0 — — -$13.6M -$7.7M
FY 2023 $0 $0 — — -$12.2M -$14.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APRE // BETA —
ENVB // BETA —